Hepcidin analogues and uses thereof

• US 9,822,157 B2
• Filed: 03/17/2014
• Issued: 11/21/2017
• Est. Priority Date: 03/15/2013
• Status: Active Grant

• Current Assignee: Protagonist Therapeutics, Inc.
• Original Assignee: Protagonist Therapeutics, Inc.
• Inventors: Smythe, Mark Leslie, Bourne, Gregory Thomas, Vink, Simone, Frederick, Brian T., Madala, Praveen, Tofteng Shelton, Anne Pernille, Fog, Jacob Ulrik
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): Hellman, Kristina M
• Application Number:
  US14/775,469
• Publication Number:
  US 20160222076A1
• Time in Patent Office: 1,345 Days
• Field of Search: None
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/12 for electrolyte homeostasis
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

Claims

1. A peptide having the following structural formula I′

2. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R1′

is hydrogen, isovaleric acid, isobutyric acid or acetyl.

3. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X′

is a peptide sequence having formula Ib′

4. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X′

is a peptide sequence having formula Ic′

5. A pharmaceutical composition which comprises at least one peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1 and a pharmaceutically acceptable carrier or excipient.

6. The peptide or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X′

-Y′

of formula I′

comprises one of the following sequences;

7. The peptide or pharmaceutically acceptable salt or solvate thereof of claim 6, comprising one of the following structures:

8. A pharmaceutical composition comprising the peptide or pharmaceutically acceptable salt or solvate thereof of claim 6 and a pharmaceutically acceptable carrier or excipient.

9. A pharmaceutical composition comprising the peptide or pharmaceutically acceptable salt or solvate thereof of claim 7 and a pharmaceutically acceptable carrier or excipient.